SAN CARLOS, Calif., Nov. 5, 2018 /PRNewswire/ -- Alkahest Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced upcoming presentations at the Society for Neuroscience 48th Annual Meeting held November 3 – 7, 2018 in San Diego. The Alkahest team will present recent preclinical data on the company's novel approaches to the treatment of neurodegenerative disorders today on November 5th and on November 7th.
"Findings from these presentations add to the growing body of research supporting our hypothesis that factors in the plasma proteome can play an important modulatory role in neurodegenerative diseases, particularly cognitive dysfunction and neurodegeneration. This presents an entirely new opportunity for therapeutic interventions," said Steven Braithwaite, Ph.D., chief scientific officer of Alkahest.
Poster Presentation Title: Synergistic effects of a plasma fraction and exercise on neurogenesis
Presenter: I. GALLAGER
Date: Monday, November 5, 2018
Session Time: 8:00 a.m. – 12:00 p.m. PT
Session: Neurogenesis and Gliogenesis: Neuronal Development I
Poster Presentation Title: Longitudinal characterization of plasma fraction efficacy on neurogenesis in aging mice
Presenter: R. A. ESTRADA
Date: Monday, November 5, 2018
Session Time: 8:00 a.m. – 12:00 p.m. PT
Session: Neurogenesis and Gliogenesis: Neuronal Development I
Poster Presentation Title: Human plasma fraction prevents age-dependent decline in neuronal activity, neurogenesis, and neuroinflammation in C57BL6 mice
Presenter: M. K. CAMPBELL
Date: Monday, November 5, 2018
Session Time: 8:00 a.m. – 12:00 p.m. PT
Session: Brain Wellness and Aging: Pharmacological and Non-Pharmacological Interventions
Presentation Title: Multi-modal impact of treatment with a human plasma protein fraction to enhance CNS function
Presenter: E. CZIRR
Date: Monday, November 5, 2018
Session Time: 1:00 p.m. – 2:45 p.m. PT
Session: Brain Wellness and Aging: Systemic Factors and Brain Function
Presentation Title: Identification and characterization of a beneficial plasma fraction with long term efficacy in the CNS
Presenter: V. KHEIFETS
Date: Monday, November 5, 2018
Session Time: 1:00 p.m. – 2:45 p.m. PT
Session: Brain Wellness and Aging: Systemic Factors and Brain Function
Poster Presentation Title: Treatment with a CCR3 antagonist rescues neuroinflammation and cognitive dysfunction in acute and chronic LPS models
Presenter: S. REGE
Date: Wednesday, November 7, 2018
Session Time: 8:00 a.m. – 12:00 p.m. PT
Session: Neurotoxicity, Inflammation, and Neuroprotection: Neuroinflammation: Animal Models
Poster Presentation Title: Human Plasma Fraction reduces the detrimental effects of alpha-synuclein overexpression in mice
Presenter: C. TUN
Date: Wednesday, November 7, 2018
Session Time: 1:00 p.m. – 5:00 p.m. PT
Session: Parkinson's Disease: Alpha-Synuclein: Models
About Alkahest
Alkahest is a privately-held clinical-stage company based in the San Francisco Bay Area developing treatments for age-related diseases, with an emphasis on neurodegeneration — a key medical challenge for our generation. The company's breakthrough research has elucidated changes in the plasma proteome in healthy aging and age-related diseases, and demonstrated that factors in the blood plasma can be augmented or inhibited in order to reverse detrimental effects of aging in both normal aging and disease models in animals. Alkahest is developing novel plasma-based therapies in collaboration with Barcelona, Spain-based Grifols, a global healthcare company and leading producer of plasma therapies. For further information, see www.alkahest.com.
Contact Information:
Joe McCracken
Vice President Business Development
Alkahest, Inc.
jmccracken@alkahest.com
Media Contact:
Michael Tattory
LifeSci Public Relations
mtattory@lifescipublicrelations.com
SOURCE Alkahest Inc.
